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Cushing’s disease (and by extension, Cushing’s syndrome) is a rare disease due to
a chronic cortisol excess, which usually has an important impact on quality of life
(QoL). It can lead to numerous comorbidities that can interfere with daily life, as
fatigability, myopathy, bone loss and fragility, increased cardiovascular risk, depression,
and cognitive alterations. Of note, psychological alterations (including depression and
anxiety) occur often, and are an important determinant of impaired quality QoL. QoL
scores using different questionnaires are poorer in comparison to healthy controls,
other pituitary adenomas and some chronic diseases. Even if some improvements
can be observed after successful treatment, recovery does not seem to be complete,
and comorbidities persist. This persistent QoL impairment has been found using
both generic and disease-specific QoL questionnaires, and is also reported by the
patients themselves, when asked directly. Multidisciplinary teams are essential to improve
patients’ well-being. Clinicians should take into account the whole scope of clinical
problems and address the different comorbidites associated with the disease. Screening
in the psychological sphere, with further intervention if necessary, can be helpful in
the management of these patients. Interventions and programs have shown promising
results, although there is a need for further development of new strategies for the benefit
of these patients.
Keywords: quality of life, health related quality of life, Cushing’s syndrome, Cushing’s disease, persistent morbidity
INTRODUCTION
Endogenous Cushing’s syndrome (CS) is a rare disease due to a chronic cortisol excess. It affects
predominantly women, with a female/male ratio ranges from 3 to 5 (1). Even if the cause of
hypercortisolism may vary (being of pituitary, adrenal or ectopic origin), pituitary origin (also
called Cushing’s disease -CD) is themost common cause of endogenous CS, affecting approximately
70% of the patients (2). This paper will deal mainly with CD, although some references to relevant
studies in CS with a high proportion of patients with CD are also included.
Comorbidities caused by CD can have an important effect on QoL. Some of the symptoms
determine physical changes that can easily be perceived by others and may affect patient’s
social interactions. These include facial plethora, weight gain, central obesity, supraclavicular fat
accumulation, hirsutism, acne, purple striae, easy bruising, poor wound healing and ulceration;
and also growth retardation in case of children (3). Furthermore, CD can also involve some
Santos et al. Quality of Life in Cushing’s Disease
morbidities that may not be easily perceived externally,
but greatly affect patients’ daily life. These include sleep
disturbances, fatigue, myopathy, hypertension, alterations
of glucose homeostasis (including diabetes mellitus and
insulin resistance), dyslipidemia, prothrombotic state, vascular
disease, atherosclerosis, menstrual and libido disturbances,
hypogonadism and body composition alterations, including
increased fat mass, reduced lean mass, and decreased bone mass
leading to osteoporosis (3). Additionally, brain studies have
also shown functional and structural alterations in the central
nervous system (4). Psychological disturbances may also be
present, including depression, anxiety, emotional irritability,
apathy and cognitive decline, which may also affect family
relationships (3, 5–10).
It is important to mention that in clinical practice a wide
variety of features are referred by the patients. In the early
stages of the disease, they may experience very few symptoms.
In other patients it may take years to find the cause of their
discomfort (11). In fact, according to data from the European
Register on Cushing’s syndrome (ERCUSYN), the median delay
to diagnosis in patients with CD is 2 years (12). Delay to diagnosis
often leads to more pronounced symptoms, which affect daily
life, especially when they include psychological disturbances
(as anxiety or depression) or troublesome symptoms, as
fatigue. This can interfere in social and family relationships,
as well as in their professional performance (11). This latter
is particularly important, as some patients may be unable
to work, with important effects on their income. Data
from the ERCUSYN database report that only 47% of the
patients were actively employed, despite a mean age of 44
years (12).
Even if symptoms usually improve after hormonal
normalization, some impairment may remain. The recovery
is slow and not all symptoms fully reverse. In fact, patients in
remission may still have a persistent increased cardiovascular
risk, body composition alterations and depression, anxiety
or impaired cognition (6, 13–15). Furthermore, pituitary
deficits requiring hormonal substitution can show up after
treatment. Therefore, patients usually complain of incomplete
recovery, both physical and psychological, affecting their
QoL (16, 17).
It is essential to perform periodic, life-long evaluations to
properly manage persistent comorbidities in order to improve
patient’s outcome (17). This also includes QoL and other
psychological aspects, which impact on the well-being and
even survival of the patients. Of note, depression in patients
in remission has been found to increase the hazard of
death, and elevate the risk of cardiovascular disease (18).
Furthermore, it is also important to consider the perspective
of the patient in order to be able to understand and approach
all problems globally that CD may involve. An interesting
study reported that 71% of the patients felt that CS had
affected their lives greatly, while 20% chose “a lot.” No patients
chose “not at all” or “very little” (8). Therefore, it would
be important to consider patient-reported outcomes during
follow-up and to provide appropriatemultidisciplinary treatment
if necessary.
QUALITY OF LIFE AND HEALTH RELATED
QUALITY OF LIFE: THE CONCEPTS
Being a complex concept, different definitions of QoL have
been developed. According to the World Health Organization
(WHO) QoL can be defined as “an individual’s perception of
their position in life in the context of the culture and value
systems in which they live and in relation to their goals,
expectations, standards and concerns” (19). In other words, QoL
could be considered a patient-reported measure that reflects
their individual definition of well-being (including patients’
expectations and physical, emotional and social aspects) (20).
QoL is a widely-used concept that has received growing
interest by clinicians and researchers in the last decades.
However, when dealing with the effects on QoL that diseases can
have, some authors prefer to use a more specific concept: health-
relatedQoL. It could be defined as “those aspects of self-perceived
well-being that are related to or affected by the presence of disease
or treatment” (21).
HOW CAN HEALTH-RELATED QUALITY OF
LIFE BE MEASURED?
Many instruments exist in order to measure health-related
QoL. When choosing a tool the essential criterion is to select
one that is validated and has good psychometric properties.
Questionnaires are the most commonly used tools to measure
health-related QoL, as they are easy to use and administer in
both clinical practice and research. Many questionnaires exist to
measure health-related QoL, and they can be classified as generic
and disease-specific.
Generic questionnaires can be used in patients with any
disease or even in healthy individuals, which is helpful to make
comparisons between different populations. Therefore, it can
be interesting to use this kind of questionnaires if we want
to compare patients with healthy controls, or if we want to
compare patients with different kinds of pituitary adenomas.
Some common generic questionnaires are Short-Form 36 (SF-
36), Short-form 12 (SF-12) or Nottingham Health Profile.
However, when dealing with a specific disease, this kind of
questionnaires may not approach some particular aspects of the
disease (20).
In contrast, disease-specific questionnaires have been
developed to evaluate specific QoL aspects of a certain disorder.
They are more sensitive to identify specific impairments related
to a disease, but as a limitation they can only be used in that
specific disease. Therefore, they are more useful for longitudinal
analysis in a population with a specific disease (for instance, in
the follow-up of a particular patient) or to compare different
patients with the same disease (17, 20).
In the case of CD, there are two disease-specific questionnaires
available: CushingQoL and Tuebingen CD-25. CushingQoL was
the first disease-specific questionnaire for CS and is a short
questionnaire consisting in 12 questions with a 5-options Likert
scale answers, with demonstrated good psychometric properties
(22–24). It was initially considered unidimensional, although
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TABLE 1 | Different questionnaires that can be used to assess quality of life in
patients with Cushing’s disease/syndrome.
Questionnaire list
Generic quality of life
questionnaires
Notingham Health Profile (NHP)
Short Form-36 (SF-36)
Short Form-12 (SF-12) (SF-36 in a short
form)
Psychological General Well Being Scale
(PGWBS)
EuroQoL-5D (EQ-5D)
World Health Organization Quality of Life
BREF (WHOQoL-BREF)
Disease-specific quality of life
questionnaires
CushingQoL
Tuebingen Cushing’s disease quality of life
inventory (Tuebingen CD-25)
Specific domains: Depression Hospital Anxiety and Depression Scale
(HADS)
Beck Depression Inventory-II (BDI-II)
Anxiety Hospital Anxiety and Depression Scale
(HADS)
Beck Anxiety Inventory (BAI)
State Trait Anxiety Inventory (STAI)
Fatigue Checklist individual strength Questionnaire
(CIS)
Modified Fatigue Impact Scale (MFIS)
Self-steem Rosenberg’s questionnaire
Sexual function Female Sexual Function Index (FSFI)
International Index of Erectile
Function (IIEF-5)
Pain Mc Gill Pain Questionnaire
Fatigue Checklist Individual Strength Questionnaire
Sleep Pittsburgh Sleep Quality Index (PSQI)
Insomnia Severity Index
a later analysis has identified two subscales: psychosocial
issues and physical problems (25). Of note, a recent study
has demonstrated that interpretation of three of the items
categorized under psychological issues can vary between different
nationalities, making it important to take this into account for
interpretation (26). The other questionnaire was developed for
patients with CD: the Tuebingen Cushing’s disease quality of life
inventory (Tuebingen CD-25). This questionnaire consists in 25
questions and includes 6 different domains: Depression, Sexual
Activity, Environment, Eating Behavior, Bodily Restrictions and
Cognition (27, 28). In this questionnaire lower scores indicate
a better QoL (in contrast with CushingQoL). Less studies are
available with this questionnaire, although some psychometric
properties had been demonstrated, as high reliability and validity,
sensitivity to change and construct and criterion validity (27, 29,
30). A strong correlation has been found when comparing scores
of both CushingQoL and Tuebingen CD-25 (R=−0.733) (30).
There are also other types of questionnaires that may not
be directly considered QoL questionnaires, although they are
able to measure a specific domain which considerably impacts
on QoL. These include comorbidities as depression, anxiety,
fatigue, sexual function, sleep, pain, or self-steem (20). Table 1
summarizes different questionnaires that can be used to assess
health-related QoL in patients with CD.
WHAT ARE THE EFFECTS OF CUSHING’S
SYNDROME ON HEALTH-RELATED
QUALITY OF LIFE?
It is now clear that CS and CD have a deleterious effect on
the QoL of the affected patients, although the extent may vary
from one patient to another. Different determinants have been
described that impact on quality of life (12, 22, 29, 31–42). A
summary can be found in Figure 1.
There are important differences in QoL between patients with
active disease and patients in remission of CD. Therefore, two
separate sections to analyzing QoL during the different phases of
the disease are presented.
EFFECTS OF ACTIVE DISEASE ON
QUALITY OF LIFE
Quality of life is clearly impaired in patients with active disease.
In CD QoL is worse than in controls and patients with any other
kind of pituitary adenomas (35, 43). QoL is similarly impaired
in pituitary-dependent CD and other causes of CS, as shown in
a cohort of patients from different European countries included
in the ERCUSYN database using CushingQoL and EuroQoL
(12, 34).
SF-36 results are low in physical and mental summary scores
compared to healthy controls matched for age and sex (35, 44).
When compared to other untreated pituitary tumors (which not
have been treated) CD were the patients with most impairment
in all SF-36 measures (43). This impairment is especially relevant
if patients do not achieve remission after treatment (specifically,
scores < 25th percentile for age and sex in most of the SF-36
domains) (45). Negative correlations have been found between
24 h urinary free cortisol and the mental component score of SF-
36 (but not with the physical component score) in patients with
CD (32).
Medical treatment can be helpful to improve QoL in active
disease. In a sample of 162 patients treated with pasireotide, a
mean improvement in CushingQoL of 11.1 points was found
after 12 months (46). Further analysis of the sample revealed
that QoL improvements were associated to lowering of urinary
free cortisol levels, reduction of both BMI and weight, and
improvement in depression (47). Twenty-four-week treatment
with mifepristone in CS has also been shown to improve the
mental and physical scores of SF-36 and depression, measured
by BDI-II (48). In a small sample of 17 patients using different
drugs sequentially (pasireotide, ketoconazole or cabergoline)
during 80 days, no statistical changes in QoL were found when
compared to basal values (no improvement or worsening).
However, improvement was found after 1 year in 3 patients that
continuedmedical treatment, suggesting that QoL improvements
after medical therapy may be found in the long run, but not so
much short-term (49).
Depression is typically found in patients with CD and is
suggested to be an earlymanifestation of CS (3, 50). At the disease
onset (or even before diagnosis) it is present in up to 25% of the
patients, and the percentage may increase over time if the disease
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FIGURE 1 | Determinants of low quality of life in Cushing’s syndrome. Modifiable factors using specific interventions have been highlighted (yellow for psychological
determinants and red for BMI).
is not treated (10). Data from the ERCUSYN have reported it
in 38% of the patients at diagnosis (12). When using specific
diagnostic criteria, major depressive disorder has been reported
in 50–80% of the active patients according to different studies,
with higher presence in the older studies (10). Furthermore, the
level of depression correlates with QoL scores measured with
SF-36 in female patients with CS, who are clearly worse than
controls (44).
Anxiety is also more prevalent in CS than in healthy
population, as evidenced with questionnaires like STAI (51). It
seems to be more prevalent in pituitary-dependent CD that in
other causes of CS (52). One study using specific diagnostic
criteria found that generalized anxiety disorder was present in
79% of the patients, while panic disorder was found in a variable
range from 3 to 37% of the patients, possibly associated with a
more chronic stage of the disease (10, 53, 54). Other psychiatric
disorders reported include mania or hypomania (3–30% of the
patients) and psychotic disorders (8% of the patients, but more
common in adrenal carcinomas, where it was found in up to 40%
of the patients) (10, 55–57). Obsessive-compulsive disorder has
also been observed in children (3).
Cognitive alterations are also commonly found in patients
suffering from CD. Memory is the cognitive function most
frequently studied, with impairment in both verbal and visual
memory (51, 58–62). Although less consistently, impairment
has also been found in other cognitive functions like executive
functions, visoconstructive skills, language, motor functions and
information processing speed (63).
This poor cognitive performance appears to be related
to specific brain specific alterations. For instance, smaller
hippocampal volumes have been found in active patients than
in controls, which have been related to learning and memory
dysfunction, and also to cortisol blood levels (64). Adult patients
with active disease also have smaller cerebellar cortex and right
amygdala volumes than healthy controls (51, 65). Reduced
amygdala volumes in comparison to controls have also been
found in children with CS (66). Left amygdala volumes are
negatively correlated with depression and anxiety scores in active
CS (but not in patients in remission) (65). Interestingly, right
cerebellar cortex volumes correlated with QoL scores, while
left cerebellar cortex volumes correlated with visual memory
(51). Other brain dysfunctions present in active CS include
changes in the concentration of different brain metabolites like
the choline/creatine ratio on the frontal and thalamic areas
(67), diffuse alterations in white matter integrity suggesting
demyelization (68) and altered activation in different brain
structures important for emotion perception (69).
Finally, other specific symptoms may have an important
impact in patient’s lives. Many suffer from insomnia, specifically
middle insomnia (59%), late insomnia (57%), or early insomnia
(29%) (70). Furthermore, although sexual function has not often
been investigated in CD, it is frequently impaired. Reduced libido
is reported in 50–69% of patients with active CS (10, 12, 55, 70).
A study in a sample of 29 sexually-active women with active
CS (89.7% with CD) showed that female sexual dysfunction was
present in 88.9% of the patients. Scores of the Female Sexual
Function Index (FSFI) were lower than in healthy controls.
More specifically, lower scores for arousal, lubrication, orgasm,
satisfaction and higher levels and frequency of pain during
intercourse were found, while no differences were found for
sexual desire. FSFI scores were positively correlated with LH
levels (which were lower in the patient sample compared with
controls) (44).
QoL is also impaired in children and adolescents. Female
to male prevalence decreases with younger age, and in fact in
prepuberal children the disease seems to be more prevalent in
males (71). Children with CD can experiment personality
changes, which typically include compulsive behavior,
moodiness, irritability and overachievement in school (72).
Some authors have reported altered amygdala and hypocampal
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function during a faces encoding task (which assesses emotional
encoding and memory), in adolescents with CS, which is not
related to memory and affective systems, in contrast with
findings in adult patients (73).
EFFECTS OF REMISSION IN QUALITY OF
LIFE
Patients in remission of CS have better QoL than active patients
measured with both disease-specific and generic questionnaires
(23, 35). The origin of the disease does not seem influence QoL,
which was similarly impaired in patients with CS, irrespective
of the cause (37). After successful treatment, improvement often
takes months or over a year, while the immediate postoperative
phase can be troublesome, including more pain, fatigability and
a poor perception of QoL (22). This in part may be due to
the glucocorticoid withdrawal syndrome, which occurs after
successful surgery. If the patient is not aware of this, the first
weeks after surgery can prove very cumbersome and worrying. A
study on patients after adrenalectomy (including 28% of patients
with CD) found that mean time for symptom resolution was at
least 7 months, and some symptoms as acne took up to a mean
of 17 months to resolve (74). In fact, not all patients perceived
themselves as fully recovered. For instance, in a cohort of 102
patients treated for CD 92% of the patients reached criteria for
biochemical cure, while only 80.4% perceived themselves as in
remission (33).
Significant improvement from baseline values can be detected
with CushingQoL 4 months after successful transsphenoidal
surgery (23). Using Tubingem 25-CD in a sample of 17 patients
with CD, improvement was found after surgery in most of the
domains, including sexual activity, environment, eating behavior,
bodily restrictions and cognition. However, no improvement
was found for depression. Predictors for improvement in QoL
after surgery were preoperative QoL impairment (meaning that
patients with poorer QoL preoperatively were more likely to
improve post surgery) and age (meaning that younger patients
were more likely to improve post surgery) (29). Another study
reported impairment in the 6 dimensions of Tuebingem 25-
CD questionnaire in patients treated for CD (85% in remission
after surgery) (75). In addition, women were more affected than
men for the dimensions of eating behavior and cognition of the
Tuebingem 25-CD questionnaire (40).
Improvements in QoL have also been reported using generic
questionnaires in patients with CD after transsphenoidal surgery.
More specifically, using SF-36, improvements were found for
bodily pain, vitality, social functioning, role limitations due
to emotional health, general health, mental health and mental
summary scores; while no improvement was found for physical
functioning, role limitations for physical health and physical
summary (35). SF-36 scores in patients surgically treated for
CD have showed more impairment in women, specifically for
physical functioning, physical role functioning and emotional
role functioning (40).
Negative illness perceptions in patients in remission of CS
are another feature which negatively affect QoL. Correlations
between the Illness Perception Questionnaire Revised (IPQ-R),
and QoL questionnaires (CushingQoL and the visual analog scale
of EuroQoL) have reflected that a worse QoL is related to affected
illness perceptions (41).
However, improvement in QoL after remission is not
complete in most of the cases, and some degree of impairment
tends to persist after cure (35, 36, 76). Table 2 reflects a list of
the most common symptoms still present after surgical remission
in patients with CS. Patients in remission still have poorer QoL
scores than healthy controls. Generic questionnaires have shown
impairment in comparison to healthy population and normative
values using different questionnaires, like the Nottingham
Health Profile (36), WHOQoL-BREF (39) or both mental and
physical summary scores of SF-36 (35, 36, 75). In addition,
patients in long-term follow-up of CD show impaired physical
functioning, measured with SF-36, when compared to patients
with non-functioning adenomas (77). CushingQoL scores are
associated with depression, anxiety, cortisol insufficiency and
self-steem (39). In a big cohort of patients included in the
ERCUSYN database, 1 year after treatment patients with CD
pituitary origin had worse QoL than those of adrenal origin.
However, in a regression analysis etiology was not related to
QoL after adjustment for baseline age, gender, remission status,
duration of active CS, glucocorticoid dependency and follow-up
time. Furthermore, when different symptoms at diagnosis were
included in a regression analysis (hypertension, diabetes mellitus,
muscle weakness, and depression) only depression was associated
with a worse CushingQoL score at last follow-up visit (34).
The presence of persistent comorbidities can also have an
important role on patient’s quality of life. In fact, having more
than two postoperative comorbidities has been reported as
a predictor of low quality of life (29). These may include
hypertension, dyslipidemia, central obesity or persistent diabetes
mellitus, among others, leading to an increased cardiovascular
risk (13). In patients treated for Cushing’s syndrome, increased
BMI has been reported as predictor of poorer quality of
life (measured with CushingQoL) (33). Control of certain
comorbidities like diabetes may require specific additional
TABLE 2 | Most common symptoms still present in patients in remission of CS
after surgical remission [adapted from Lindsay et al. (35); sample of 343 patients










Forgetfulness 35.7 Anxiety 28.4
Trouble sleeping 33.3 Facial hair 27.6
Depression 31.2 Feelings of
sadness
27.6
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chronic medication and lifestyle changes, which may influence
patient’s perception of well-being.
Self-assessment of the remission status provides some
interesting information, and may be discordant with the
biochemical status. In a cohort of 102 patients treated for
CD, CushingQoL scores were higher in patients that perceived
themselves as in remission when compared to patients that
perceived themselves as having persistent disease. This group
that perceived themselves as biochemically cured also had lower
scores in anxiety and depression, measured with HADS. When
patients with real biochemical remission were analyzed, those
who perceived themselves as cured had better QoL than patients
who did not feel “cured,” although they also had a longer duration
of follow-up. The authors suggested that this may reflect a
discordance between biochemical and psychological recovery
times, psychological recovery being slower. On the other hand,
patients who were hypercortisolemic had poorer QoL scores
and higher depression scores compared to patients who were
biochemically cured (33).
Patients perceive that their body changes dramatically after
onset of the disease, and that it never returns to its original
size. However, no clear relationship was found between QoL and
characteristics of a drawing test, were patients drew themselves
before, during and after CS treatment (78). Patients in remission
of CS also showed a lower body satisfaction in comparison with
normative values measured with the Body Satisfaction Score.
Body satisfaction is also associated with the social relations
domain of the WhoQoL questionnaire. In the same study, 61.9%
of the patients had a low or very low self-steem (39).
Hypopituitarism contributes to worse QoL in patients treated
for CD. In a longitudinal study of 58 patients who had
undergone transsphenoidal surgery (and radiotherapy in 19%
of the patients), hypopituitarism was present in 52% of the
patients, and was an independent predictor of worse QoL (36).
In line with these findings, a study of 99 patients with CD and
24 patients with CS of adrenal origin found that both groups
had impairment in most of the QoL dimensions compared
to controls (with no differences between both patient groups).
However, when pituitary patients were analyzed, patients without
any pituitary deficiencies had better QoL scores (specifically in
CushingQoL and the energy item of the NHP questionnaire) and
also in the items of fatigue and motivation form the Checklist
Individual Strength Questionnaire (a questionnaire designed to
measure fatigue) when compared to patients with deficiencies.
Even if impairment was still present in comparison to controls,
in the group without pituitary deficiencies it was only found in
half of the dimensions evaluated (37). Other studies have also
found higher fatigue in CS patients in remission than in healthy
controls, measured with MFI-20 and MFS (36, 79).
Patients with CD that underwent bilateral adrenalectomy,
compared to patients who underwent other treatments, had
poorer QoL, measured with SF-36 (mainly in bodily pain, general
health, vitality and social functioning) and CushingQoL. They
also presented worse depressive scores measured with the BDI.
The major predictor of poor QoL was adrenal insufficiency (42).
This is in line with a prior study, where even if patients reported
improvement in their QoL after bilateral adrenalectomy, scores
from SF-36 were all lower that the general population (80).
Different studies have described higher depression and
anxiety levels in comparison with literature values, healthy
controls and non-functioning adenomas, measured with
different questionnaires, including HADS, BDI, BDI-II and or
STAI (36, 37, 51, 75, 81, 82). Increased age and male gender have
been related to less anxiety levels in a cohort of patients treated
by transsphenoidal surgery for CD (33). Current depression
scores, measured with BDI-II and CES-D, have been associated
to delay to diagnosis in patients in remission of CS (38). Patients
had higher scores than controls for depression, anxiety, stress
perception and QoL. Interestingly, levels of blood brain-derived
neurotrophic factor (usually expressed in brain areas that control
mood and stress response), were related to higher depression,
anxiety and stress, and to decreased affective balance (38).
Another study found that patients in remission of CD
presented higher depression, anxiety, apathy and irritability
than healthy controls. Depression (measured with HADS) was
positively influenced by remission duration; while irritability
(measured with the Irritability Scale) was related to radiotherapy,
and on the other hand apathy (measured with the Apathy
Scale) was associated by level of education. Those patients
also presented maladaptative personality traits, with poorer
performance in several scales of the Dimensional Assessment of
Personality Pathology short-form in comparison with controls.
Of note, when anxiety and depression were controlled as
covariates only differences in affective liability and anxiousness
remained statistically significant (81). In another study from the
same group it was demonstrated that patients with pituitary
adenomas had less effective coping strategies than healthy
controls, although patients with CD sought more social support
than patients with non-functioning adenomas (83). In a focus
group study including 6 patients with CD some maladaptive
coping strategies (as overdoing or problems with acceptance)
were identified as possible contributors of low QoL (84). In
fact, a further study found that maladaptative coping strategies
(mainly depressive coping, trivialization, and wishful thinking)
were correlated to different measures, indicating a relationship
with poorer QoL (measures with both Tuebingem CD-25 and
SF-36) and higher depression, anxiety and embitterment (40).
Furthermore, QoL scores were also related to embitterment
(measured with the Bern embitterment questionnaire-BEI).
Some degree of embitterment was found in more than a half of
the patients compared to reference values. Specifically 36.8% of
the patients had a medium degree of embitterment, 18.7% had an
above-average degree of embitterment and 3.5% had an extreme
degree of embitterment (40)
Cognitive function, including memory and executive
functions, remains impaired after cure of CD. This has been
found 1 year after biochemical cure (85, 86), 3 years after
surgery for CS (9) and also in patients with long-term remission,
with lower scores when compared to healthy controls and
non-functioning adenomas (6, 82, 87, 88). One study in CS in
long-term remission reported that cognitive alterations were
independent of concomitant fatigue and affective disorders,
while etiology was not related to cognitive symptoms (82).
In line with findings for cognitive function, brain alterations
may also persist in patients in remission. They include altered
functionality (as changes in the concentrations of different brain
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metabolites or loss of white matter integrity due to decreases
of axial diffusivity) (89–93) and structure (4, 7, 88), with lower
brain volumes than controls in adults (affecting total volumes
and gray matter) (51). Subjective loss of brain volume can
also be found in 86% of the patients with CD after cure
(94). In contrast, in children reduced brain volumes seem to
reverse after cure (66). Some authors report a slight increase
of the hippocampus and right caudate volume after cure of
CD (95, 96). Hippocampal volume increase was also related
to word learning improvement (95). Other studies in patients
in remission of CS have found no differences in hippocampal
volumes, when compared to healthy controls (7, 97), although
smaller hippocampal volumes were found in patients with
severe memory impairments (97). Of note, brains of patients in
remission show a higher degree of white matter lesions (visible
in the MRI) when compared to controls and patients with active
disease. The severity of white matter lesions has been correlated
to duration and degree of hypertension, reflecting the increased
prevalence of cardiovascular risk factors in CS. Furthermore,
lower gray and total brain matter volumes have been found when
compared to normal controls, and brain volume was correlated
to 10-year cardiovascular risk (6).
Even after surgery children may also still experience low
QoL, although improvements may be found in comparison
to levels during active disease (98). In a sample of children
and adolescents, incomplete recovery of the hypothalamic-
pituitary-adrenal axis 1 year post-treatment was related to
poorer QoL in physical and psychosocial domains, measured
with a generic health-related QoL questionnaire (the child
health questionnaire-parent report). Furthermore, changes in
physical function scores were inversely associated with BMI
(98). Most of the persistent comorbidities found in adults,
as altered body composition, can also be found in children
(99). However, brain function and volume seems to be affected
by cortisol excess in a different way when compared to
adults. In fact, a recovery of brain volume has been described
1 year after cure, with a decrease in cognitive function
and a decline in school performance, with no associated
psychopathology (66). Brain plasticity in these younger patients
may contribute to these findings which differ from the
experience in adults. Furthermore, in children with CS, final
height is very often compromised, lower than midparent
height (100).
HINTS TO IMPROVE PATIENT’S QUALITY
OF LIFE
Clinicians play an important role in helping patients to improve
their QoL. First of all, it is important to treat all comorbidities. As
reported before, some modifiable factors can have a great impact
in QoL (as depression, anxiety, poor coping strategies, low self-
steem, negative illness perceptions or high BMI). Patients should
be asked for their symptoms and needs and referred to specialists
if necessary, including psychologists and/or psychiatrists. It
would also be important to inform the patients on the persistent
adverse events that CS may have on their QoL, so inappropriate
expectations can be avoided (77). Giving printed information
may be helpful, so the patients can have time to analyze and
review it if necessary. Additionally, an empathic relationship is
essential, as in fact the doctor-patient relationship can have an
important impact on patient outcome, and even survival (101).
Patients with CS of any cause may benefit from educational
interventions. A 9-month educational nursing program
in patient groups with CS (most of them in remission)
demonstrated improvements in sleep patterns, pain, healthy
lifestyle and physical activity, which positively influenced
QoL. This program consisted on 4 educational sessions (2 of
them including also family members) and one follow-up visit.
The topics included basic information of CS, management
of comorbidities, self-care, practice of balanced diets and
recommendations for healthy lifestyle (102). In this line, the
Endocrine Society Guidelines recommend educating patients
with CS on the clinical features of remission of CS, but also
their families (103). Given the low prevalence of the disease
(approximately 39.1 patients per million inhabitants) patients
may feel very lonely and not understood (104). Therefore,
support groups can also be helpful to help patients deal with CS
and its consequences. Many options exist, which do not need to
be face-to-face (facebook, whatsapp or websites can be used).
Clinicians can facilititate contacts to the patients if local groups
are available. Finally, maintaining healthy habits and lifestile
is also important, positively influencing patient outcome and
well-being (10).
A study on German and US patients with CS in remission
(only CD for Germany) explored patient’s needs through a
questionnaire. Patients reported that good medical care and
skilled doctors where what helped them most to cope with
the disease (48.8% US, 44.4% Germany), followed by support
from family, friends and religion (36.9% US, 31.7% Germany).
Regarding educational and support programs, most of the
patients preferred internet-based programs (89.3% US, 75.4%
Germany). However, cultural differences and specific needs may
differ in different populations of patients with CS (105). In other
chronic diseases programs that improve self-manegement (where
the patient has a more active role) have lead to better health status
and increased QoL (105). Consequently, it would be helpful to
develop specific programs for patients with CD too.
In conclusion, health-care providers can use different
strategies to improve patient’s well-being. Screening and
management of persistent comorbidities, including psychological
aspects, is essential. Education on the disease and what to expect
can be very helpful, as well as an empathic attitude, to make
the patient aware that the symptoms, signs and limitations he
or she is experiencing may be related to the prior diagnosis of
CS, and can be approached to improve their day-to-day outcome.
Group programs have shown promising results, but still few are
available, so this is a pending issue for the future.
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